Songbing Qin

机构：Soochow University, University of Pittsburgh Medical Center, Jiangsu Province Hospital, First Affiliated Hospital of Soochow University, Nanjing Medical University · ORCID：0000-0001-7056-1741

发表论文 108 篇 · 总被引 1171 次 · h-index 16

代表论文

• LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) (2024 · Annals of Oncology · 被引 91)
• High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers (2025 · Cell Death and Disease · 被引 10)
• Global patterns and burden of soft tissue and extraosseous sarcomas: trends from 1990 to 2021 (2025 · BMC Cancer · 被引 8)
• Efficient Biomarker for Immunotherapy: Measuring Broad Clones Effector Tumor Antigen-Specific T Cells in the Blood of Esophageal Cancer Patients (2024 · Analytical Chemistry · 被引 6)
• Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies (2025 · Clinical and Translational Medicine · 被引 5)
• Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer (2025 · Journal of Gastrointestinal Oncology · 被引 4)